Publications

onc201

Biological activity of weekly ONC201 in adult recurrent glioblastoma patients

Neuro Oncol. 2020 PMID: 31702782

Arrillaga-Romany I, Odia Y, Prabhu VV, et al.

onc201

Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201

J Neurooncol. 2019 PMID: 31456142

Chi AS, Tarapore RS, Hall MD, et al.

imipridones

Defining structure activity relationships for GPCR engagement and anti-cancer efficacy of imipridone small molecules

ACR Annual Meeting 2019

Prabhu VV, Kawakibi AR, Madhukar NS, et al.

onc201

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

J Immunother Cancer. 2019 PMID: 31118108

Stein MN, Malhotra J, Tarapore RS, et al.

imipridones

Mitochondrial ClpP-mediated proteolysis induces selective cancer cell lethality

Cancer Cell 2019 PMID: 31056398

Ishizawa J, Zarabi SF, Davis RE, et al.

onc212

Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia.

Leukemia. 2019 PMID: 31127149

Nii T, Prabhu VV, Ruvolo V, et al.

onc201

Dopamine receptor D5 is a modulator of tumor response to dopamine receptor D2 antagonism

Clin Cancer Res. 2019 PMID: 30559168

Prabhu VV, Madhukar NS, Gilvary C, et al.

onc201

Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment

J Clin Invest. 2018 PMID: 29533922

Wagner J, Kline CL, Zhou L, et al.

onc212

Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP

Oncotarget 2017 PMID: 29137221

Lev A, Lulla AR, Wagner J, et al.

onc201

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget

Oncotarget. 2017 PMID: 29108308

Arrillaga-Romany I, Chi AS, Allen JE, et al.